Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 27, 2006 Brian Lawler	One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors.
The Motley Fool May 27, 2005 Charly Travers	Vertex's Cautious Optimism The company's innovative hepatitis C drug has made May a month to remember. Investors, take note.
The Motley Fool November 6, 2007 Brian Lawler	No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns?
The Motley Fool April 27, 2005 Charly Travers	Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years.
The Motley Fool May 28, 2009 Anders Bylund	Of Robots and Rocket-Powered Returns Intuitive Surgical is a stock that meets your need for speed and security, all at once.
The Motley Fool April 25, 2008 Brian Lawler	Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
The Motley Fool March 27, 2007	Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note.
The Motley Fool February 3, 2006 Stephen D. Simpson	Phase 2 for Intuitive Surgical Now that the initial rush is over, it's time for Intuitive Surgical to build a lasting business. Investors need to be careful with this one.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool October 30, 2006 Brian Lawler	Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data.
The Motley Fool October 28, 2011 Brian Orelli	Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug.
The Motley Fool October 31, 2011 Brian Orelli	When Getting Beat Down Is No Big Deal Merck is getting smacked down by Vertex Pharmaceuticals in the hepatitis C market, but it has the bulk to take a beating.
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool March 2, 2006 Roger Friedman	The Quandary of the Double Here is a comparison of two life-changing moments -- a stock double and twins! -- and how to deal with each.
The Motley Fool June 14, 2005 John Reeves	3 Growth Stocks for Your Portfolio Check out a few companies we think are poised for greatness: Blue Nile... Intuitive Surgical... Shanda Interactive...
The Motley Fool December 11, 2006 Jack Uldrich	Intuitive Surgical's Beating Heart Investors, there are a lot of reasons to like Intuitive Surgical. Better software will continue to improve surgeons' performance levels in meeting the demanding requirements of cardiovascular surgery.
The Motley Fool January 8, 2009 Brian Orelli	Lowered Guidance? No Problem! Investors with long-term horizons will likely see this downturn as a small blip on the general upward trend of Intuitive Surgical.
The Motley Fool April 23, 2008 Brian Lawler	Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir.
The Motley Fool February 10, 2005 Charly Travers	Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
The Motley Fool December 15, 2011 Luke Timmerman	Vertex Names Jeff Leiden As New CEO, Staring Down Tough New Competition What does new leadership mean for Vertex's future?
The Motley Fool October 30, 2006 Brian Lawler	InterMune Plays "Let's Make a Deal" The biopharmaceutical 's deal with Roche could mean stiff competition for rival Vertex. Investors, take note.
The Motley Fool February 9, 2006	Dueling Fools: Intuitive Surgical Intuitive Surgical has been a big winner, more than doubling over the past year, but will the good times continue?
The Motley Fool October 30, 2006 Dan Caplinger	Keep It Simple Once you are comfortable with an investment method that works for you, you should rarely feel compelled to change a successful strategy.
The Motley Fool April 21, 2009 Brian Richards	Wonderful Company, but Is the Price Fair? Intuitive Surgical has one of the simplest -- and prettiest -- business models around. But is 24.6 times earnings -- its current multiple -- a "fair price?"
The Motley Fool April 26, 2011 Luke Timmerman	FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex?
The Motley Fool September 26, 2008 Brian Lawler	Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages.
The Motley Fool June 4, 2010 Brian Richards	Intuitive Surgical: Strengths, Weaknesses, Opportunities, Threats A look inside the business of the da Vinci robot maker.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
The Motley Fool April 4, 2005 John Reeves	Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier.
The Motley Fool May 17, 2011 Luke Timmerman	Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex.
The Motley Fool August 4, 2010 Ryan McBride	How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.
The Motley Fool July 27, 2004 Charly Travers	Cash Concerns at Vertex New royalties might not help offset losses at the pharmaceutical, so it's time to look at the drug pipeline.
The Motley Fool October 25, 2008 Wade Michels	How to Catch the Big One Have you ever heard the phrase "disruptive innovation"? If not, too bad, because if you spot a disruptive innovation early enough, it can make you a fortune.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool July 22, 2005 Stephen D. Simpson	Bio-Tech's Robot-Coaster Ride Intuitive Surgical is a high-growth, high-opportunity stock with a history of earnings-related volatility.
The Motley Fool February 6, 2009 Brian Orelli	1,111 Reasons to Love This Company Intuitive Surgical's already installed base of 1,111 da Vinci surgical machines will drive sales through the use of consumables.
The Motley Fool November 30, 2011 David Williamson	Health Care's 5 Worst November Flops These stocks had a terrible month.
The Motley Fool November 25, 2011 Brian Orelli	7 Black Friday Biotech Bargains Get in at the right time to maximize your returns.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool July 29, 2011 Brian Orelli	Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start.
The Motley Fool April 22, 2005 Stephen D. Simpson	Success Is Intuitive Surgical robotics continues to grow, and Intuitive Surgical dominates the market. It's important to note, though, that valuation is a tricky matter when you're dealing with fast-growing companies that are basically pioneering entirely new businesses.
The Motley Fool October 16, 2008 Brian Orelli	Foolish Forecast: Robots on the Cheap Intuitive Surgical releases earnings in a few hours. Here are some premonitions to tide you over as you anxiously wait the news.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool October 26, 2011 Selena Maranjian	Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you.
The Motley Fool February 8, 2011 Brian Orelli	What Will Intuitive Surgical Do for an Encore? Intuitive Surgical managed just a 10% year-over-year increase in revenue from sales of its da Vinci Surgical Systems in the fourth quarter of last year. Yet its total revenue increased a solid 21%. How?
The Motley Fool October 21, 2009 Brian Orelli	Slicing and Dicing Intuitive Surgical's Quarter Not the best we've seen, but still solid.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool October 21, 2005 Rick Aristotle Munarriz	The Fool's Look Ahead Monday: CNET Networks reports in... Tuesday: Intuitive Surgical is impressing the market with its fat margins... Wednesday: Janus and T. Rowe Price step up to the earnings podium... etc.